Hillary Stires

15PUBLICATIONS
91CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Counselling, wellbeing and community servicesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy.

Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura

|Jun 23, 2025
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies.

Joseph M Unger, Hillary S Andrews, Laura A Levit

|Apr 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura

|Sep 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.

Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard

|Aug 15, 2024
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy.

Brittany A McKelvey, Elizabeth Garrett-Mayer, Donna R Rivera

|Jun 17, 2024
An Evaluation of Novel Oncology Approvals with a PMR/C for Assessing Data in Racial and Ethnic Populations Underrepresented in Premarket Clinical Trials.

Grace Collins, Hillary S Andrews, Brittany McKelvey

Pageof 3

Frequent Collaborators

9 joint publications

Mark Stewart

8 joint publications

Brittany McKelvey

5 joint publications

Jeff D Allen

3 joint publications

Elizabeth Garrett-Mayer